ArticleBMC urology2025
Initial experience of thulium fiber laser in retrograde intrarenal surgery for ureteral and renal stones in Japan: surgical outcomes and safety assessment compared with holmium: yttrium-aluminum-garnet with MOSES technology.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Complications of thulium fiber laser lithotripsy: a systematic review and meta-analysis by the EAU-YAU endourology and urolithiasis working group.World journal of urology · 2026Pooled it
- Thulium Fiber Laser Versus Holmium Laser for Ureteroscopic Lithotripsy: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Magneto Ho:YAG laser versus Thulium Fiber Laser for laser lithotripsy during flexible ureteroscopy with a flexible and navigable ureteral access sheath.International urology and nephrology · 2026Article
- Review
- Ureteroscopy in pediatric urolithiasis: techniques, challenges, and outcomes.World journal of urology · 2025Review
- A Comparative Evaluation of Holmium:YAG and Thulium Fiber Lasers in Urinary Stone Treatment.Cureus · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThulium fiber laser (TFL) has been used for the treatment of ureteral and renal stones in Japan since October 2023. However, there are no reports on the initial results of TFL in Japan. This study aimed to assess the initial results of TFL in retrograde intrarenal surgery (RIRS) and to compare them with those of holmium: yttrium-aluminum-garnet (Ho: YAG) laser with MOSES technology.
methodsThis retrospective single-center study compared perioperative results, complications, and the "stone-free" rate (defined as ≤ 2 mm fragments on computed tomography 1 month after RIRS) between the TFL (60 W) (group A, n = 48) and Ho: YAG laser with MOSES technology (120 W) (group B, n = 48) laser. The inclusion criteria were renal or ureteral stones ≤ 20 mm in diameter and those scheduled for single-stage RIRS.
resultsThe two groups had similar baseline patient characteristics. No significant differences were found in operative time (45 vs. 54 min, P = 0.10), laser time (15 vs. 10 min, P = 0.12), stone-free rate (97.9% vs. 95.8%, P = 1.00), ureteral injury (2.1% vs. 8.3%, P = 0.36), or postoperative fever (0% vs. 4.2%, P = 0.49) between groups A and B. However, significant differences were found in basketing time (7 vs. 21 min, P < 0.01) between groups A and B.
conclusionsOur study showed that RIRS with TFL had similar results and no difference in complications compared to RIRS with Ho: YAG laser with MOSES technology. The TFL had a significantly shorter basketing time than the Ho: YAG laser with MOSES technology. Furthermore, future research is needed to determine suitable laser settings for the TFL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.